SCHEMBL2676276

SCHEMBL2676276

O=C(O)c1c(CN2CCN(CC(O)CO)CC2)n(-c2ccccc2)c(=O)c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.50
ADRA2B P18089 1/20 0.50
ADRA2C P18825 1/20 0.50
MAPT P10636 3/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
ABCB1 P08183 2/20 0.38
P4HB P07237 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PLK1 P53350 3/20 0.38
MAPK1 P28482 1/20 0.38
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HTR7 P34969 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2675783 0.88 MAPT (0.39) MAPTLMNAGAAP4HBNPSR1
SCHEMBL2676908 0.87 NPSR1 (0.42) MAPTLMNAGAAP4HBNPSR1
SCHEMBL2676280 0.85 KMT2A (0.41) MAPTLMNAGAAP4HBNPSR1
SCHEMBL1719001 0.84 TACR2 (0.43) MAPTLMNAGAAP4HBNPSR1
SCHEMBL2675904 0.84 MAPK1 (0.41) MAPTLMNAGAAP4HBNPSR1
SCHEMBL2675238 0.84 P4HB (0.51) MAPTLMNAGAAP4HBNPSR1
SCHEMBL2676766 0.84 MCL1 (0.46) MAPTLMNAGAANPSR1MEN1
SCHEMBL2676392 0.84 MAPK1 (0.45) MAPTLMNAGAAP4HBNPSR1
SCHEMBL2675569 0.84 ALDH1A1 (0.46) MAPTLMNAGAAP4HBNPSR1
SCHEMBL1717374 0.83 TACR3 (0.47) ADRA2AADRA2BADRA2CLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 ADRA2A 564/4885ADRA2B 486/4885ADRA2C 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.